This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Preliminary Program

*Program & Topics/Titles are Subject to Change 

Thursday, July 9, 2020

  • 08:00 13:00

    Registration

  • 08:30 09:55

    Session 9: Antivirals: Challenges and New Frontiers

    8:30 - 9:00 | Plenary Lecture 7: Will Reinfection be a Problem in High Risk Populations?
                           Julie Bruneau - CRCHUM, Montreal, QC, Canada

    9:00 - 9:25 | Keynote Lecture 11: Epigenetic Signatures Post HCV Cure by Direct-Acting Antivirals
                           Meital Gal-Tenamy - Bar-Ilan University, Israel

    9:25 - 10:25 | Oral Presentations selected from Abstracts (4 x 15min) 

  • 10:25 10:45

    Coffee Break

  • 10:45 12:15

    Session 10: Vaccines

    10:45 - 11:15 | Plenary Lecture 8: Systems Biology to Predict Vaccine Efficacy
                               Rafick Sekaly - Case Western Reserve University, Cleveland, OH, USA

    11:15 - 11:35 | Keynote Lecture 12: Update on Immunological Analysis of HCV Vaccine Trial
                               Andrea Cox - Johns Hopkins School of Medicine, Baltimore, MD, USA

    11:35 - 12:15 | Panel Discussion on the Future of Vaccine Development for HCV 

  • 12:15 13:30

    Lunch

  • 13:30 14:30

    Session 10: Vaccines (Continued)

                            | Oral Presentations selected from Abstracts (4 x 15min)

  • 14:30 15:00

    Flash Poster Presentations

  • 15:00 15:30

    Coffee Break

  • 15:30 16:00

    Closing Lecture: HCV, the Next 30 Years

    Michael Houghton - University of Alberta, Edmonton, AB, Canada

  • 16:00 16:15

    Closing Remarks